Meeting
2024 ASCO Genitourinary Cancers Symposium
SABRE: Assessment of safety and efficacy of 64Cu-SAR-BBN in patients with PSMA-negative biochemical recurrent prostate cancer.
Authors
Luke T. Nordquist
Urology Cancer Center, PC, Omaha, NE
Luke T. Nordquist , Eva Lengyelova , Andrei Iagaru , Brandon Robert Mancini , Hong Song , Medhat Osman , David Josephson , Frankis Almaguel , Daniel Saltzstein , Michelle Parker , Robert M. Miller , Neal D. Shore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Diagnostics and Imaging
Clinical Trial Registration Number
NCT05407311
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr TPS346)
DOI
10.1200/JCO.2024.42.4_suppl.TPS346
Abstract #
TPS346
Poster Bd #
Q20
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
PET imaging with 68Gallium-labelled ligand of prostate-specific membrane antigen (68Ga-HBED-PSMA) for staging of biochemical recurrent prostate cancer after radical prostatectomy.
First Author: Tobias Maurer
Poster
2024 ASCO Genitourinary Cancers Symposium
Utility of PSMA PET/CT for imaging ductal carcinoma of the prostate.
First Author: Ahmed M. Mahmoud
Poster
2023 ASCO Annual Meeting
Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): An international multicenter retrospective study.
First Author: Boris A. Hadaschik
Poster
2024 ASCO Genitourinary Cancers Symposium
![Real-life data on [<sup>177</sup>Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in France.](https://d201v5jt9ylckg.cloudfront.net/315/15621/230193/230193_A132_poster_pv.jpg)
Real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in France.
First Author: Guilhem Roubaud